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SCIENCE FOR JUDGES VI INTRODUCTION
Margaret A. Berger∗
Once again, the Journal of Law and Policy is publishing
papers relating to science and law that had their inception at a
Science for Judges program for federal and state judges.1 The
program, held at Brooklyn Law School on November 4 and 5,
2005, was the sixth in a series of conferences funded by the
Common Benefit Trust established in the Silicone Breast Implant
Products Liability Litigation. These programs have been presented
under the auspices of Brooklyn Law School’s Center for Health,
Science and Public Policy in collaboration with the Federal
Judicial Center, the National Center for State Courts, and the
Committee on Science, Technology and Law of the National
Academies of Science.
November’s program conference was devoted to an exploration
of evidence-based medicine. Understanding the methodology that
evidence-based medicine brings to an evaluation of medical
research seemed highly compatible with the objectives of these
programs for judges because medical experts are among the most
commonly used experts in court proceedings. They testify
frequently in a wide variety of cases, such as toxic tort cases,
∗
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Professor Berger is the Director of the Science for Judges Program.
1
Papers from previous Science for Judges programs can be found in 12 J.L.
& POL’Y 1, 1-53 (2003) (papers discussing the practice of epidemiology and the
science produced by administrative agencies); 12 J.L. & POL’Y 485, 485-639
(2004) (papers discussing toxicology and epidemiology); 13 J.L. & POL’Y 1, 1179 (2005) (papers discussing the integrity of scientific research and forensic
evidence in criminal proceedings); 13 J.L. & POL’Y 499, 499-647 (2005) (papers
discussing Agent Orange and human behavior research); 14 J.L. & POL’Y 1, 1209 (papers discussing risk assessment and data disclosure and protection). All
papers are available in electronic form at http://brooklaw.
edu/centers/scienceforjudges/papers.php.
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medical malpractice actions, and insurance coverage disputes. The
articles that follow have two major objectives: 1) to examine the
role of evidence-based medicine in improving decision making by
policy makers in a number of different arenas, and 2) to provide
the reader with an understanding of the statistical concepts and
technical vocabulary that researchers use when they employ the
methodology of evidence-based medicine in reaching a conclusion
about a disputed medical intervention, or in deciding that no
conclusion is as yet warranted.
The Fox-Greenfield article, Helping Public Officials Use
Research Evaluating Health Care,2 provides background
information by tracing the history of the evidence-based medicine
movement and its progress in bringing information about outcomes
to the attention of policy makers. It suggests that the judiciary too
will benefit from knowing how to access systematic reviews and
make use of their findings. Gibson’s article, When Good
Information Truly Matters: Public Sector Decision Makers
Acquiring and Using Research to Inform Their Decisions,3 follows
up on the Fox-Greenfield discussion by examining a trend on the
part of public officials to inform themselves rather than relying
solely on information that others provide. This trend is leading
public officials to seek, commission, and evaluate research needed
to make decisions in the public interest. As an example, he then
explores the Drug Effectiveness Review Project (DERP), a
collaboration of fifteen states and two other organizations that
commissions and uses systematic reviews of global research to
inform drug purchasing decisions in their Medicaid, corrections,
workers’ compensation, general health care, and employee benefits
programs. In addition to explaining DERP’s process, he analyzes
the criticisms that have been voiced about this initiative.
Bero’s article, Evaluating Systematic Reviews and MetaAnalyses,4 begins by explaining the strengths and importance of
2

Daniel M. Fox & Lee Greenfield, Helping Public Officials Use Research
Evaluating Healthcare, 14 J.L. & POL’Y 531 (2006).
3
Mark Gibson, When Good Information Truly Matters: Public Sector
Decision Makers Acquiring and Using Research to Inform Their Decisions, 14
J.L. & POL’Y 553 (2006).
4
Lisa A. Bero, Evaluating Systematic Reviews and Meta-Analyses, 14 J.L.
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systematic reviews, and by providing an example of a metaanalysis that showed that a widely-used treatment had no effect.
She then turns to the complex question of how systematic reviews
are evaluated for bias. After discussing how to set up protocols
before a study begins, to ensure that researchers cannot adjust their
analysis midstream if they are disappointed by the conclusions that
are emerging, she turns to defining various types of bias and how
bias can be detected and eliminated. Judges and lawyers should
find her exposition extremely useful in evaluating studies on which
expert witnesses seek to rely. Her discussion also points out,
however, how difficult it may be to arrive at a definitive answer.
Although evidence-based medicine seeks to arrive at statistically
significant research results that are true, Bero’s paper
acknowledges the many different obstacles that may have to be
overcome.
The Lerner-Robertson article, When There Are No Randomized
Controlled Trials: A Case History of a Controversial Procedure
for Metastatic Breast Cancer,5 is a fascinating and troubling
account of the use of bone marrow transplants to treat advanced
cases of breast cancer even though the technique’s effectiveness
had not been studied. Lerner and Robertson paint a vivid picture of
the various forces that combined to demand the transplant
procedure despite the lack of scientific information, the huge cost,
and deaths that resulted from the treatment. This cautionary tale of
oncologists, politicians, scientific fraud, and advocates for women
provides a remarkable glimpse of the various players, including the
courts which became involved because of suits by women denied
insurance coverage. The article also explains how ultimately the
ineffectiveness of the transplants was shown despite the absence of
randomized controlled trials by using an approach that combined
data from uncontrolled trials. Certainly, the value of evidencebased approaches is validated by this experience.
But there is a limit to how useful evidence-based medicine can
be in judicial proceedings. Much will depend on the question
& POL’Y 571 (2006).
5
Jeffrey C. Lerner & Diane C. Robertson, When There Are No Randomized
Controlled Trials: A Case History of a Controversial Procedure for Metastatic
Breast Cancer, 14 J.L. & POL’Y 597 (2006).

BERGER MACROED 7-30-06.DOC

528

7/30/2006 12:33 PM

JOURNAL OF LAW AND POLICY

before the court. Systematic reviews of randomized controlled
studies are the gold standard in determining whether an
intervention is efficacious and may therefore be extremely useful
in malpractice cases and insurance disputes. However,
observational studies are much more likely to play a role in
assessing causation in toxic tort cases.
It is, however, not only the issue that will determine the
usefulness of an evidence-based medicine approach. This approach
evaluates the strength of existing evidence. Often, of course, in
legal proceedings there will be no studies that satisfy the standards
of evidence-based medicine. What does the judge do then? How
should gaps in knowledge be treated? Can inferences be drawn
against a party that possesses information which it failed to supply,
such as negative trials, or that failed to conduct additional
research? Can one combine other kinds of evidence with studies
that are insufficient in themselves to prove the issue in
controversy? How does one synthesize these different types of
evidence? What is the applicable standard of proof that scientific
evidence must meetis it the rigorous standard that the
practitioners of science-based medicine use when they decide a
conclusion is warranted, or is it the lower preponderance of
evidence standard that applies in civil litigation? What role do
conflicts of interest or bias play? These are all fascinating
questions that are beyond the scope of this Science for Judges
program. Some have been discussed at previous programs and at
the Science for Judges VII program which was held in March 2006.
Papers from that conference will be published in a forthcoming
issue of the Journal of Law and Policy. The oral presentations
made at the March program are available now at the Science for
Judges website.6
The articles that follow provide rich food for thought for all
those interested in the interaction of science and law and the role of
public policy in decision making. The Science for Judges program
and the Journal of Law and Policy wish to thank Dan Fox for
6

Brooklyn Law School, Center for Health, Science and Public Policy,
Science for Judges, http://www.brooklaw.edu/centers/scienceforjudges/
events.php.
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